Two-bit Hits for May 19

I thought Moffitt was going to have an abstract at ASCO 2012 (see here). I was wrong. I think we will see and hear more from Moffitt soon, possibly later this month and next.

In the last year Provectus management has materially increased its rhetoric regarding the systemic effect of PV-10. As an example:

• In the last 12 months (May 2011 to May 2012), the company issued 26 PRs. In 9 of these PRs, the company and third parties mentioned the systemic effect a total of 22 times (14 and 8, respectively). 
• Prior to that (May 2010 to May 2011), the company issued 20 PRs. In 4 of these PRs, the company and third parties mentioned the systemic effect 10 times (9 and 1, respectively).

What will the reaction be to the final MM Phase 2 data? Or, to PV-10 doing better in compassionate use? Or, to PV-10 doing better than expected in the MM P3 trial?

Awareness grows (a visual representation of blog readership):